NCT06914869

Drug-Drug Interaction Potential of Mavorixafor

A Phase I, Randomized, Open-label, Drug-drug Interaction Study to Assess the Effect of Multiple Doses of a Moderate and a Strong CYP3A Inducer on the Pharmacokinetics and Safety of Mavorixafor in Healthy Male and Female Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 38 (actual)
• Sponsor: X4 Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The main purpose of this study is to evaluate drug-drug interaction (DDI) of orally administered mavorixafor with cytochrome P3A (CYP3A) inducers carbamazepine (a strong CYP3A inducer) or efavirenz (a moderate CYP3A inducer) in healthy male and female participants.

Conditions

• Healthy Participants

Interventions

Type	Name	Description
DRUG	Mavorixafor	Mavorixafor will be administered per schedule specified in the arm description.
DRUG	Carbamazepine	Carbamazepine will be administered per schedule specified in the arm description.
DRUG	Efavirenz	Efavirenz will be administered per schedule specified in the arm description.

Timeline

• Start date: 2025-02-18
• Primary completion: 2025-05-19
• Completion: 2025-05-19
• First posted: 2025-04-06
• Last updated: 2025-07-01

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study